Comparative Marker Assessment in Small Cell Lung Cancer with Good and Poor Prognosis Abstract #1162

Introduction: Small cell lung cancers (SCLC) are highly aggressive and poorly differentiated neuroendocrine neoplasms which comprise ̴̴̴15 % of all lung malignancies.
Aim(s): In a panel of patients with diagnosed SCLC with poor and good prognosis we investigated the prognostic impact by analyzing protein and mRNA expression levels of 9 molecular markers. Furthermore we studied the influence of therapeutic interventions on the prognosis.
Materials and methods: Formalin-fixed, paraffin-embedded tumor samples of 27 SCLC patients with good prognosis (survival ≥ 30 months) and 19 patients with poor prognosis (survival < 30 months) were analyzed for the receptors SSTR1, 2A, 3, 4, 5, CXCR4 and the proliferation markers Ki-67, TOP2A and RacGAP1 by means of immunohistochemistry and RT-qPCR.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Lydia Schmidt

To read results and conclusion, please login ...

Further abstracts you may be interested in

#833 The Chemokine Receptor CXCR4 – Differential Expression in Bronchopulmonary Neuroendocrine Neoplasms
Introduction: The CXCR4 is a plasma membrane chemokine receptor, which is involved in organogenesis, hematopoiesis and inflammation. Additionally, an over-expression is described for many neoplastic tissues. Here, an involvement in tumor progression, metastasis, adaptation to hypoxia and in stem cell survival is postulated.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Christiane Anne Reimann
#1723 Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin
Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, whereas the chemokine receptor CXCR4 is considered to be present mainly in highly proliferative and advanced tumors.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Amelie Lupp
#879 The Assessment of Proliferation in BP-NEN Entities Based on the Three Proliferation Markers Ki-67, TOP2A and RacGAP1
Introduction: The extent of cell proliferation as an important component of carcinogenesis can be detected in tumor tissues by means of various factors.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Elisa Specht
#877 Immunohistochemical and qRT-PCR-Based Evaluation of Somatostatin Receptor 1 to 5 Expression in 92 Patients with Bronchopulmonary Neuroendocrine Neoplasms
Introduction: Little is known about the somatostatin receptor (SSTR) status in bronchopulmonary neuroendocrine neoplasms (BP-NEN), comprising typical carcinoids (TC), atypical carcinoids (AC), small cell lung cancer (SCLC) and large cell neuroendocrine lung carcinomas (LCNEC).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Elisa Specht
#1038 Co-Expression of Somatostatin and CXCR4 Receptors as Targets for Diagnostics and Treatment in Intestinal Neuroendocrine Neoplasms.
Introduction: Somatostatin receptors (SSTR) are widely distributed in well-differentiated neuroendocrine tumors (NET) and serve as primary targets for diagnostics and treatment. An overexpression of the chemokine receptor CXCR4, in contrast, is considered to be present mainly in highly proliferative and advanced carcinomas.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
Keywords: sstr